SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  November 26, 2021

IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

000-19125

33-0336973
(Commission File No.)

(IRS Employer Identification No.)

2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (760) 931-9200



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered
Common Stock, $.001 Par Value
“IONS”

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 19, 2021, Peter N. Reikes, a member of the Board of Directors (“Board”) and Finance Committee of the Board of Ionis Pharmaceuticals, Inc. (the “Company”), notified the Company that he is resigning from the Company’s Board effective November 21, 2021. Mr. Reikes has accepted a position with the U.S. Food and Drug Administration that requires him to step off the Company’s Board to avoid a perception of a conflict of interest. The Company thanks Mr. Reikes for his advice and leadership as a member of the Company’s Board. The Company wishes Mr. Reikes success in his new endeavor.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
Ionis Pharmaceuticals, Inc.
   
Dated:  November 26, 2021
By:
/s/ Patrick R. O’Neil
   
Patrick R. O’Neil
   
Executive Vice President, Chief Legal Officer and General Counsel



Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Ionis Pharmaceuticals Charts.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Ionis Pharmaceuticals Charts.